Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Malignant Pleural Effusion in NSCLC
NCT02942043Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2016
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in malignant pleural effusion (MPE) (3 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Pleural Effusion Objective Response Rate at 1 year. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT02942043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942043.